

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 16, 2022

**STRATA Skin Sciences, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**000-51481**

(Commission File Number)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**13-3986004**

(I.R.S. Employer Identification No.)

**5 Walnut Grove Drive, Suite 140**

**Horsham, Pennsylvania 19044**

(Address of principal executive offices, including zip code)

**(215) 619-3200**

(Registrant's telephone number, including area code)

**NOT APPLICABLE**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

On May 16, 2022, Strata Skin Sciences (the “Company”) announced the appointment of Michael Goodman as Head of International Sales. Mr. Goodman’s experience in international sales includes his position as Associate Director of International Sales for Obagi Medical Products where he led, reset and supported a network of global distribution partners. Most recently, he was a U.S. regional sales director for Pulse Biosciences, advancing commercialization efforts and strategic direction. Earlier, Mr. Goodman founded MG Consulting Group, advising on industry, sales training, and product expertise to organizational leadership in the medical device industry. His career also includes various International and domestic sales and marketing positions with Syneron-Candela and for more than a decade, with Sound Surgical Technologies, which was subsequently acquired by Solta Medical. Upon Solta Medical’s acquisition by Valeant Pharmaceuticals, he led the international surgical specialties and global distribution channels for Valeant.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

[99.1 Press release, dated May 16, 2022.](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**STRATA SKIN SCIENCES, INC.**

Date: May 16, 2022

By: /s/ Christopher Lesovitz  
Christopher Lesovitz  
Chief Financial Officer

## **STRATA Skin Sciences Names Michael E. Goodman as Head of International Sales**

**Horsham, Pa, May 16, 2022** — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that Michael E. Goodman has been named STRATA's Head of International Sales.

In this newly created role, Mr. Goodman will be a key member of STRATA's expanding global commercial leadership team, with oversight of the Company's commercial and sales strategy in Europe, Asia and Latin America. In addition, as the Head of International Sales, Mr. Goodman assumes responsibility for providing STRATA with key insights into successful sales strategies for international expansion and to drive these strategies to fruition across targeted global markets.

"We are delighted to welcome Michael to the STRATA team," said Bob Moccia, Chief Executive Officer of STRATA. "He brings expansive and highly relevant sales and operational management experience to our leadership team, which will be key to our international expansion success. We believe that his experience in the medical laser space, particularly in dermatology and aesthetics, will be an important asset for STRATA to leverage. We look forward to supporting his growth and vision for our company."

Mr. Goodman's experience in international sales includes his position as Associate Director of International Sales for Obagi Medical Products where he led, reset, and supported a network of global distribution partners. Most recently, he was a U.S. regional sales director for Pulse Biosciences, advancing commercialization efforts and strategic direction. Earlier, Mr. Goodman founded MG Consulting Group, advising on industry, sales training, and product expertise to organizational leadership in the medical device industry. His career also includes various International and domestic sales and marketing positions with Syneron-Candela and for more than a decade, with Sound Surgical Technologies, which was subsequently acquired by Solta Medical. Upon Solta Medical's acquisition by Valeant Pharmaceuticals, he led the international surgical specialties and global distribution channels for Valeant.

"I am excited to join STRATA and support its growth by increasing its international presence," said Mr. Goodman. "I have been in the medical laser therapy space for nearly two decades and I look forward to leveraging that experience to aid STRATA in further building its international sales strategy and exposure among distributors and dermatologists."

### **About STRATA Skin Sciences, Inc.**

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear treatment system utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company's proprietary XTRAC, XTRAC Momentum™ 1.0 and Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. Additionally, STRATA's recently acquired assets related to Theravant Corporation's TheraClear system allows the company to expand into the U.S. acne care market.

STRATA's unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

### **Investor Contact**

Jack Droogan  
(203) 585-4140  
ir@strataskin.com

---

---